department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

MK-6194 · pharmadog

pharmadog
drugs
MK-6194

drug

patient view →

MK-6194

Phase 2updated 2mo ago

by $MRK Merck & Co., Inc.

Phase 2

community read0 votes

indications

indications

IBD (Crohn's + UC)

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

indication

Ulcerative Colitis

phase

phase_2

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying MK-6194

phase2A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)terminatedn=169
phase1A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)completedn=57
phase2Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)terminatedn=149
phase1Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)completedn=72
phase1A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)completedn=37
phase1MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)completedn=16